

Introduction to **AMVUTTRA® (vutrisiran)** Targeting ATTR-CM at the Source

AMVUTTRA® (vutrisiran) Educational Program

Please join your colleagues for a discussion sponsored by Alnylam Pharmaceuticals.

Presented by:

Dia Smiley, DO
Cleveland Clinic Weston

Program Overview:

Join us for an educational discussion focused on the management of transthyretin-mediated amyloidosis (ATTR-CM) and the clinical role of AMVUTTRA.

This program will:

- Discuss a hypothetical patient case
- Review the mechanism of action for AMVUTTRA
- Provide an overview of ATTR-CM
- Review the clinical profile of AMVUTTRA
- Discuss access and patient support resources

Event Details:

WHO: Dia Smiley, DO, Cleveland Clinic Weston

WHEN: Tuesday, June 30, 2026 | 6:30 PM ET

WHERE: Okeechobee Steakhouse, 2854 Okeechobee Blvd, West Palm Beach, FL

Additional Information:

This program is intended for US healthcare professionals only. Guests and spouses may not attend. Per PhRMA guidelines, meals may be reportable and alcohol will not be provided. This program is non-accredited and does not offer CME credits.

For full prescribing information, please visit:

www.amvuttrahcp.com

Contact:

tthomas@alnylam.com | (561) 254-0226